Determining the expression rate of the IgM and IgA in B cell lymphomas by immunohistochemistry

Area of Science:

• Immunology
• Oncology
• Pathology

Background:

• Non-Hodgkin lymphoma (NHL) is a heterogeneous group of B-cell malignancies.
• Immunoglobulin (Ig) expression on lymphoma cells is a key diagnostic and prognostic factor.
• Understanding IgA and IgM expression in NHL can aid in subclassification and targeted therapy.

Purpose of the Study:

• To determine the expression rates of IgA and IgM in B-cell lymphoma.
• To correlate IgA and IgM expression with CD20 positivity in NHL specimens.
• To contribute data on the immunophenotypic characteristics of NHL.

Main Methods:

• Immunohistochemical staining was performed on 52 paraffin-embedded NHL specimens.
• Specimens were initially assessed for CD20 expression.
• CD20-positive cases were further evaluated for IgA and IgM expression.

Main Results:

• 36 out of 52 cases (69.2%) were CD20-positive.
• Among CD20-positive cases, 15 (41.7%) expressed IgM, 9 (25%) expressed IgA, and 4 (11.1%) expressed both IgA and IgM.
• The mean age of CD20-positive patients was 50.0 +/- 23.6 years, with a male predominance (61%).

Conclusions:

• IgM and IgA expression is present in a significant proportion of CD20-positive B-cell lymphomas.
• These findings align with existing literature on immunoglobulin expression in NHL.
• Further research may explore the clinical implications of specific IgA/IgM expression patterns in NHL.